ARPA-H | IGoR - Intelligent Generator of Research

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

ARPA-H is seeking multidisciplinary teams to build an AI-enabled interoperable research ecosystem through the Intelligent Generator of Research (IGoR) program. The goal is to dramatically accelerate biomedical research and therapeutic development by creating mechanistic disease models, AI-driven experiment orchestration, standardized protocols, and a distributed network of validated laboratories. ARPA-H states the system is intended to enable researchers to create validated knowledge “at least 10x more rapidly than conventional approaches.”

This is a 5-year, 3-phase program under the ARPA-H Proactive Health Office. ARPA-H anticipates awarding approximately three Other Transaction (OT) agreements to teams capable of addressing all four technical components of the program.

Solution Summaries are due by 06/25/2026, 12:00 PM Eastern Time. Full Proposals are due by 08/06/2026, 12:00 PM (Noon) Eastern Time. Companies interested in applying should begin organizing teaming structures and registrations immediately, particularly because SAM.gov registration can take 7–10 business days.

How much funding would I receive?

The solicitation does not specify total funding amounts or individual award sizes.

ARPA-H states it anticipates making:

• “Multiple Other Transaction (OTs) Agreements”

• Approximately three awards to multidisciplinary teams

The solicitation does not specify:

• Ceiling amounts

• Floor amounts

• Cost share requirements

• Phase-specific funding allocations

What could I use the funding for?

Funding is intended to support development of the IGoR ecosystem, including:

• Mechanistic disease models encoding causal biological relationships across scales

• An AI orchestration layer that identifies knowledge gaps and designs experiments

• A layered protocol architecture enabling reproducible experimentation

• A distributed marketplace of validated laboratories returning standardized data

ARPA-H expects performers to address all four technical components as part of an integrated system.

The solicitation states the objective is to:

• Eliminate longstanding inefficiencies in research

• Accelerate development of therapies for complex diseases

• Enable validated knowledge generation at least 10x faster than conventional approaches

Are there any additional benefits I would receive?

Potential additional benefits include:

• Participation in a high-visibility ARPA-H initiative

• Access to collaboration and networking opportunities through the Proposers’ Day

• Ability to form multidisciplinary teams and partnerships

• Flexibility associated with Other Transaction (OT) agreements compared to traditional federal contracts

ARPA-H also states that:

• Resource sharing is encouraged

• A recording of the Proposers’ Day will be posted publicly

The solicitation does not specify additional commercialization support, follow-on funding pathways, or transition assistance.

What is the timeline to apply and when would I receive funding?

Key dates:

• Proposers’ Day: T.B.D.

• Solution Summaries due: 06/25/2026, 12:00 PM Eastern Time

• Full Proposals due: 08/06/2026, 12:00 PM (Noon) Eastern Time

Submission process:

1. Submit a Solution Summary

2. Receive feedback from ARPA-H indicating whether proposal submission is encouraged or discouraged

3. Submit a full proposal

ARPA-H notes that proposers may still submit full proposals even if discouraged after the Solution Summary review.

The solicitation does not specify:

• Award announcement dates

• Negotiation timelines

• Expected project start dates

• Timing of funding disbursement

Where does this funding come from?

This funding comes from:

• Advanced Research Projects Agency for Health (ARPA-H)

• Proactive Health Office

Program:

• Intelligent Generator of Research (IGoR)

Solicitation Number:

• ARPA-H-SOL-26-155

Who is eligible to apply?

Eligible applicants may include:

• Universities

• Non-profit organizations

• Small businesses

• Other commercial entities

ARPA-H states that all sources capable of satisfying the government’s needs may respond unless otherwise restricted.

Restrictions include:

• Federally Funded Research and Development Centers (FFRDCs) generally may not participate as prime or sub-performers unless ARPA-H determines unique capabilities are necessary

• Government entities and government employees are generally prohibited

• Current ARPA-H support service providers are ineligible

• Certain foreign entities and individuals are prohibited under the CHIPS and Science Act of 2022 and related national security restrictions

Applicants must:

• Be registered in SAM.gov

• Have a valid Unique Entity Identifier (UEI)

• Maintain active SAM.gov registration through award

ARPA-H states new SAM.gov registrations take an average of 7–10 business days.

What companies and projects are likely to win?

ARPA-H states it anticipates selecting approximately three multidisciplinary teams capable of addressing all four components of the IGoR ecosystem.

Competitive proposals will likely demonstrate:

• Integrated multidisciplinary capabilities

• AI and machine learning expertise

• Mechanistic disease modeling capabilities

• Experimental protocol standardization

• Large-scale laboratory coordination capabilities

• Reproducible data generation approaches

• Ability to execute across all technical areas described in Appendix A

The solicitation emphasizes:

• Bold and unconventional research directions

• Accelerated knowledge generation

• Interoperable research infrastructure

• Reproducibility and standardization

ARPA-H also encourages resource sharing and teaming.

Are there any restrictions I should know about?

Key restrictions include:

• FFRDCs and government entities generally cannot serve as prime or sub-performers

• Current ARPA-H support contractors are ineligible

• Certain foreign entities and individuals are prohibited

• Submissions containing proprietary information must be clearly marked

• All Solution Summaries must:

  • Be in English

  • Use sans serif fonts no smaller than 11-point

  • Be limited to five pages (excluding cover pages and references)

ARPA-H also notes:

• It will not reimburse proposal preparation costs

• Late submissions caused by delayed registration may not be considered

• Large language models (LLMs) may be used during review under controlled security conditions

The solicitation does not specify:

• Mandatory cost share

• Manufacturing requirements

• Export control classifications

• Intellectual property terms beyond standard OT agreement references

How long will it take me to prepare an application?

This opportunity will likely require substantial preparation effort because:

• ARPA-H expects multidisciplinary teams

• Applicants must address all four major technical components

• Teaming and integration strategies will likely be critical

• OT-based proposals are often highly technical and milestone-driven

Preparation activities may include:

• Forming consortium relationships

• Finalizing technical architecture

• Building execution and management plans

• Completing SAM.gov registration

• Preparing a Solution Summary followed by a full proposal

The solicitation does not specify expected proposal preparation timelines.

How can BW&CO help?

BW&CO can help your team:

• Assess fit with the IGoR program objectives

• Build a competitive teaming strategy

• Translate technical concepts into ARPA-H-ready proposal language

• Develop Solution Summaries and full proposals

• Structure OT-compliant submissions

• Build milestone-driven technical plans

• Coordinate multidisciplinary proposal development

• Prepare management, commercialization, and execution materials

Additional Resources

Review solicitation here.

ARPA-H | HEARING - Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

ARPA-H’s Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy (HEARING) program is seeking teams capable of developing the first minimally invasive, brain-connected hearing restoration platform that can read and write auditory information directly with the brain’s auditory cortex. The program aims to move beyond traditional hearing aids and cochlear implants by creating closed-loop systems that can reduce background noise in real time, personalize hearing restoration, and restore hearing close to normal for people with mild to severe hearing loss.

This is a highly ambitious, systems-level program requiring integrated teams spanning neurotechnology, wireless power and communications, AI/ML auditory decoding, clinical audiology, neurosurgery, regulatory affairs, and device commercialization. ARPA-H explicitly requires proposals to address all three Technical Areas (TAs) and all three program phases.

Solution Summaries are due Monday, June 29, 2026, 2:00 PM ET. Full Proposals are due Friday, August 14th, 2026, 2:00 PM ET. Companies interested in leading or participating in a team should begin partner discussions immediately because the solicitation strongly emphasizes multidisciplinary integration and system-level execution.

How much funding would I receive?

The solicitation states that ARPA-H anticipates making “Multiple Other Transaction (OTs) Agreements.”

The solicitation does not specify:

• Total program funding

• Individual award sizes

• Ceiling amounts

• Floor amounts

• Number of awards

• Funding by Technical Area

• Funding by phase

Cost sharing is “Encouraged (Optional).”

What could I use the funding for?

Funding is intended to support development of a fully integrated closed-loop hearing restoration platform across three Technical Areas:

• TA1: Intracortical Device(s)

  • Minimally invasive brain interfaces

  • Recording and stimulation technologies

  • Wireless brain-connected devices

  • Cortical targeting technologies

  • Implant delivery systems

• TA2: Dynamic Sound Modulator

  • Wearable hearing-aid-like devices

  • Wireless power transfer

  • Bidirectional communications

  • Closed-loop auditory systems

  • External processing hardware

• TA3: Auditory Read & Write Algorithms

  • AI/ML auditory decoding

  • Neural signal interpretation

  • Personalized hearing restoration algorithms

  • Closed-loop neuroprocessing software

  • Auditory stimulation and modulation systems

The program also supports:

• Animal studies

• Human data collection

• Pre-clinical validation

• Regulatory engagement with FDA

• First-in-human (FIH) studies

• Manufacturing scale-up

• Clinical protocols

• System integration activities

The solicitation requires all proposals to address all three TAs and all program phases.

Are there any additional benefits I would receive?

Potential additional benefits include:

• Direct engagement with ARPA-H

• FDA engagement and regulatory planning support

• Participation in ARPA-H performer meetings

• Collaboration opportunities with multidisciplinary teams

• Potential commercialization pathways

• Clinical translation support

• Access to a high-visibility national neurotechnology initiative

ARPA-H states it is uniquely positioned to:

• Convene multidisciplinary teams

• Set aggressive system-level milestones

• Provide commercialization support

• Provide regulatory support

The solicitation also encourages:

• Open or permissive licensing for interoperability components

• Shared data standards

• Shared benchmarking tools

• Shared reference datasets

What is the timeline to apply and when would I receive funding?

Key dates are:

• Proposers’ Day: Monday, June 8, 2026

• Questions & Answers (Q&A) due date: Monday, June 15th, 2026, 5:00 PM ET

• Solution Summaries due date: Monday, June 29, 2026, 2:00 PM ET

• Full Proposals due date: Friday, August 14th, 2026, 2:00 PM ET

The HEARING program is structured as a 4.5-year effort consisting of:

• Phase 1: Research & Development (18 months)

• Phase 2: Pre-Clinical (24 months)

• Phase 3: Clinical / First-in-Human Studies (12 months)

The solicitation does not specify:

• Award announcement dates

• Contract negotiation timelines

• Expected project start dates

• Payment schedules

Where does this funding come from?

This funding comes from:

• Advanced Research Projects Agency for Health (ARPA-H)

• Health Science Futures (HSF) Office

Program title:

• Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy (HEARING)

Solicitation number:

• ARPA-H-SOL-26-154

Announcement type:

• Innovative Solutions Opening (ISO)

Who is eligible to apply?

Eligible proposers include:

• Universities

• Non-profit organizations

• Small businesses

• Other than small businesses

The solicitation states:
“All responsible sources capable of satisfying the Government’s needs may submit a proposal to this ISO.”

Additional eligibility requirements and restrictions include:

• Proposals must address all three Technical Areas and all program phases

• Proposals must be submitted under a single prime awardee

• Teams must include interdisciplinary expertise

• Teams must include representative end-user, clinical, and regulatory expertise

• Proposers may submit a maximum of:

  • One (1) proposal as prime proposer

  • Two (2) proposals as sub proposer

• SAM.gov registration is required

Non-U.S. entities:

• May participate subject to applicable regulations and restrictions

• ARPA-H will prioritize work conducted in the United States

Ineligible entities include:

• Federally Funded Research and Development Centers (FFRDCs) as prime or sub performers, unless specifically approved

• Government entities and federal employees as performers

• Organizations with unmitigable organizational conflicts of interest

• Certain foreign entities identified under applicable federal statutes

What companies and projects are likely to win?

The strongest proposals will likely include:

• Fully integrated multidisciplinary teams

• Existing expertise in neurotechnology and BCIs

• Strong preliminary data

• Demonstrated ability to execute complex hardware/software integration

• FDA and clinical strategy experience

• Real-world hearing restoration validation plans

• Commercialization pathways

• Human data collection capabilities

• Experience with wireless implantable systems

• AI/ML auditory decoding expertise

ARPA-H explicitly states that proposals should:

• Be innovative and feasible

• Be supported by preliminary evidence

• Address major technical risks

• Include clear mitigation strategies

• Demonstrate commercialization potential

• Consider end-user experience and accessibility

• Improve speech-in-noise outcomes

• Support real-world usability

Projects that are likely to be noncompetitive include:

• Incremental improvements to existing hearing aids

• Solutions addressing only one TA

• Programs lacking system integration capability

• Solutions requiring craniotomy or craniectomy for the final TA1 device

• Technologies without sufficient preliminary evidence

• Systems with cumbersome form factors

Are there any restrictions I should know about?

Yes. Key restrictions include:

Technical restrictions:

• Proposals must address all TAs and all phases

• Final TA1 devices cannot require surgical skull access (e.g., craniotomy or craniectomy)

• Implanted batteries subdurally or deeper into the brain are out of scope

• Solutions cannot rely on cumbersome form factors

• Solutions functioning only in controlled environments may be deemed non-responsive

Administrative restrictions:

• Solution Summary submission is required before submitting a Full Proposal

• Submissions must be in English

• Submission must occur through the ARPA-H Solution Submission Portal

• SAM.gov registration is required

Program restrictions:

• FFRDCs and Government entities are generally prohibited from participating as performers

• Current ARPA-H support contractors may be ineligible due to OCI restrictions

• Certain foreign entities are prohibited

Regulatory requirements:

• FDA engagement is expected

• IND/IDE approvals or equivalent permissions are required before Phase 3

• Human subject research approvals are required where applicable

The solicitation also notes that ARPA-H may impose publication restrictions for projects involving sensitive information.

How long will it take me to prepare an application?

This will likely require a substantial proposal effort.

The solicitation requires:

• A single integrated proposal

• Coverage of all three Technical Areas

• Coverage of all three phases

• Detailed technical milestones

• Regulatory planning

• Clinical planning

• Manufacturing planning

• Animal study plans

• Human data collection strategies

• System integration plans

• Commercialization considerations

• Cost proposals

• Extensive interdisciplinary teaming

Most teams will likely need:

• Multiple institutional partners

• Clinical collaborators

• Regulatory consultants

• Neurotechnology expertise

• AI/ML expertise

• Hardware and firmware engineering support

• Program integration leadership

Teams without existing partnerships and preliminary work may face compressed timelines before the:

• Solution Summaries due date: Monday, June 29, 2026, 2:00 PM ET

• Full Proposals due date: Friday, August 14th, 2026, 2:00 PM ET

How can BW&CO help?

BW&CO can support:

• Go/no-go evaluation

• Teaming strategy and partner identification

• Technical narrative development

• System integration positioning

• ARPA-H proposal strategy

• Workplan and milestone development

• Commercialization positioning

• Regulatory strategy framing

• Competitive differentiation

• Budget development support

• Full proposal writing and coordination

• Submission management

For HEARING specifically, BW&CO can also help teams:

• Translate highly technical neurotechnology concepts into ARPA-H-ready narratives

• Align deliverables with program metrics

• Structure multidisciplinary proposals across all three TAs

• Position preliminary data effectively

• Build compelling transition and clinical translation strategies

Additional Resources

Review solicitation here.

CDMRP - Prostate Cancer Research Program (PCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Prostate Cancer Research Program (PCRP), administered by the Congressionally Directed Medical Research Programs (CDMRP), is expected to release multiple funding opportunities supporting innovative, high-impact prostate cancer research with clinical relevance. The program is focused on eliminating death and suffering from prostate cancer through new therapies, improved clinical care, survivorship research, and better understanding of disease progression.

This is currently a pre-announcement. Funding opportunity announcements will be posted later on Grants.gov and will include official pre-application and application deadlines. At this time, the application deadline is not specified in the solicitation.

How much funding would I receive?

Funding amounts depend on the award mechanism.

• Data Science Award

  • Maximum allowable funding is $1.4 million for total costs

  • Maximum period of performance is 3 years

• Early Investigator Research Award

  • Maximum allowable funding is $630,000 for total costs

  • Maximum period of performance is 3 years

• Idea Development Award

  • Established Investigator Option:

    • Maximum allowable funding is $1.7M for total costs

    • Maximum period of performance is 3 years

  • New Investigator Option:

    • Maximum allowable funding is $2.1M for total costs

    • Maximum period of performance is 4 years

• Physician Research Award

  • Maximum allowable funding is $1.1M for total costs

  • Maximum period of performance is 4 years

The solicitation states that total costs include direct and indirect costs.

What could I use the funding for?

The allowable use of funds depends on the award mechanism.

Data Science Award supports research that develops or uses quantitative and analytical approaches, processes, and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in areas including:

• Analysis of clinically annotated datasets

• Analysis of “-omics” data

• Artificial intelligence and machine learning

• Bioinformatics

• Computational biology

• Digital pathology

• Epidemiology

• Medical imaging

Early Investigator Research Award supports prostate cancer research conducted by early-stage investigators under mentorship from experienced researchers.

Idea Development Award supports innovative, high-risk and high-gain approaches to prostate cancer research.

Physician Research Award supports mentored research experiences for physicians pursuing careers in prostate cancer research and clinical practice.

Several mechanisms allow clinical research and correlative studies associated with ongoing or completed clinical trials, but clinical trials themselves are not allowed under these awards.

Are there any additional benefits I would receive?

Potential additional benefits include:

• Access to CDMRP-administered funding programs with national visibility

• Support for researcher career development and mentorship under the Early Investigator Research Award and Physician Research Award

• Flexibility for multidisciplinary and multi-institutional collaboration under certain award mechanisms

• Opportunity to pursue high-risk, high-gain research concepts through the Idea Development Award

The solicitation also encourages, but does not require:

• Preliminary data for several award mechanisms

• Multidisciplinary projects

• Multi-institutional projects

What is the timeline to apply and when would I receive funding?

This notice is a pre-announcement only.

The solicitation states that:

• Funding opportunity announcements will be posted later on Grants.gov

• Once released, the funding opportunity announcements will include pre-application and application deadlines

• The PCRP requires submission of a letter of intent prior to full application submission

• Before full application submission, the CDMRP requires submission of a pre-application through eBRAP prior to the pre-application deadline

The application deadline is not specified in the solicitation.

The timing for award decisions or funding distribution is not specified in the solicitation.

Where does this funding come from?

The funding comes from the FY26 Defense Appropriations Act and is administered through:

• Defense Health Agency Research and Development (DHA R&D)

• Medical Research and Development Command (MRDC)

• Congressionally Directed Medical Research Programs (CDMRP)

The funding opportunity is part of the FY26 Prostate Cancer Research Program (PCRP).

Who is eligible to apply?

Eligibility depends on the award mechanism.

Data Science Award

• Independent investigators at all levels

Early Investigator Research Award

• Early-career investigators possessing a doctoral degree, or equivalent, with fewer than 3 years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training

Idea Development Award
Established Investigators:

• Independent investigators at all levels

New Investigators:

• Independent investigators that:

  • Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award

  • Either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree, excluding residency or family medical leave

Physician Research Award

• Early-career clinician investigators that are either:

  • In the last year of an accredited medical residency or medical fellowship program

  • Within 5 years of initiating a faculty appointment, including instructor positions or equivalent

Additional personnel requirements apply for mentored mechanisms.

What companies and projects are likely to win?

Projects are likely to be competitive if they:

• Address one or more of the PCRP’s overarching challenges

• Demonstrate clinical relevance and potential impact

• Propose innovative approaches to prostate cancer research

• Focus on improving outcomes for patients with lethal prostate cancer

• Advance survivorship, wellness, or clinical care

• Improve understanding of progression to lethal prostate cancer

The solicitation specifically emphasizes:

• Innovation and impact equally under the Idea Development Award

• High-risk and high-gain approaches

• Quantitative and analytical methods for large and complex prostate cancer datasets under the Data Science Award

Are there any restrictions I should know about?

Key restrictions include:

• Applications cannot support clinical trials under all listed award mechanisms

• Data Science Award applications cannot support prospective recruitment of human subjects

• Several awards require submission of a letter of intent prior to full application submission

• Full applications must conform to the final funding opportunity announcements available on Grants.gov

• Certain mechanisms require mentorship and researcher development plans

• Physician Research Award applications strongly encourage protection of at least 20% of the PI’s time for prostate cancer research

The solicitation states that this announcement is only a pre-announcement and should not be construed as an obligation or promise by the government.

How long will it take me to prepare an application?

The solicitation does not specify expected preparation time.

However, applicants should anticipate preparing:

• A pre-application through eBRAP

• A letter of intent

• A full application package

• Research development plans for mentored mechanisms

• Supporting documentation related to eligibility, mentorship, and project scope

Because official funding opportunity announcements and deadlines have not yet been released, applicants may benefit from beginning project planning early.

How can BW&CO help?

BW&CO can help companies and research teams:

• Evaluate which FY26 PCRP mechanism best aligns with their technology or research program

• Position projects around the program’s stated overarching challenges

• Develop commercialization and impact narratives

• Coordinate scientific, clinical, and subcontractor partners

• Manage proposal development, writing, compliance, and submission

• Prepare pre-applications, letters of intent, and full proposals

Additional Resources

Review solicitation here.

CDMRP - Neurofibromatosis Research Program (NFRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Neurofibromatosis Research Program (NFRP), administered by the Congressionally Directed Medical Research Programs (CDMRP), is expected to fund multiple award mechanisms supporting innovative, high-impact neurofibromatosis (NF) and schwannomatosis research. The program is specifically focused on improving understanding, diagnosis, treatment and quality of life outcomes for people affected by NF and schwannomatosis, including Service Members, Veterans and their families.

This is currently a pre-announcement. The CDMRP states that funding opportunity announcements will be released on Grants.gov at a later date and will contain official pre-application and application deadlines. At this time, application deadlines are not specified. The program recommends investigators begin planning early.

How much funding would I receive?

The FY26 NFRP includes multiple anticipated award mechanisms with varying funding levels:

• Exploration-Hypothesis Development Award

  • Maximum allowable funding: $160,000 total costs

  • Maximum performance period: 2 years

• Investigator-Initiated Research Award

  • Maximum allowable funding: $525,000 total costs

  • Maximum performance period: 3 years

  • Applications using the Qualified Collaborator or NF Open Science Initiative options may request up to $575,000 total costs

• Neurofibromatosis Research Academy – Leadership Award

  • Maximum allowable funding: $2.4 million total costs

  • Maximum performance period: 4 years

• Neurofibromatosis Research Academy – Scholar Award

  • Maximum allowable funding: $1.2 million total costs

  • Maximum performance period: 4 years

• Synergistic Idea Award

  • Maximum allowable funding: $3.2 million total costs

  • Maximum performance period: 3 years

Total costs include both direct and indirect costs.

What could I use the funding for?

Funding is intended to support innovative and impactful neurofibromatosis and schwannomatosis research projects.

Potential project areas include:

• Schwannomatosis and NF2-related research

• Biomarker and endpoint validation

• Data science applications

• Pain and cognitive manifestation research

• Sleep-related NF research

• Genomics, epigenetics and systems biology

• Drug discovery and target identification

• Preclinical efficacy studies

• Nutritional and environmental modifiers of NF

• Health services research

Specific award mechanisms also support:

• Early-stage exploratory concepts

• Multi-investigator collaborative projects

• Early-career investigator development

• Multi-institutional mentoring academies

• Pilot research projects within academy structures

Clinical trials are not allowed under the listed award mechanisms.

Are there any additional benefits I would receive?

Depending on the award mechanism, applicants may receive additional benefits such as:

• Access to collaborative research partnerships

• Participation in the NF Open Science Initiative

• Intensive mentoring and career development

• National networking opportunities

• Participation in a virtual NF research academy

• Access to NF Consumer Consultant Panels

• Multi-institutional collaboration opportunities

The Neurofibromatosis Research Academy mechanisms are specifically designed to support mentorship, networking and long-term investigator development in the NF field.

What is the timeline to apply and when would I receive funding?

The CDMRP released this pre-announcement on April 22, 2026.

Application deadlines are not specified in the pre-announcement. The CDMRP states that official funding opportunity announcements will later be posted on Grants.gov and will include pre-application and application deadlines.

The program requires submission of a pre-application through eBRAP prior to full application submission.

Periods of performance vary by award mechanism:

• 2 years for Exploration-Hypothesis Development Awards

• 3 years for Investigator-Initiated Research Awards

• 4 years for Academy Leadership Awards

• 4 years for Academy Scholar Awards

• 3 years for Synergistic Idea Awards

The solicitation does not specify anticipated award start dates or funding disbursement timelines.

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act through the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility depends on the award mechanism.

Exploration-Hypothesis Development Award:

• Investigators at all career levels

• Includes postdoctoral fellows or equivalent

Investigator-Initiated Research Award:

• Investigators at or above the level of Assistant Professor or equivalent

• Must commit a minimum of 10% effort throughout the award

Neurofibromatosis Research Academy – Leadership Award:

• Academy Director must be an established NF investigator at or above Associate Professor or equivalent

• Academy Deputy Director must also be at or above Associate Professor level and affiliated with a different institution

Neurofibromatosis Research Academy – Scholar Award:

• Scholars must be early-career investigators within 10 years of terminal degree or clinical fellowship

• Requires an eligible Career Guide who is an established NF investigator

Synergistic Idea Award:

• Investigators at or above the level of Assistant Professor or equivalent

Additional eligibility requirements may be included in the final funding opportunity announcements.

What companies and projects are likely to win?

The NFRP is seeking projects that are:

• Innovative and high-impact

• Clinically relevant

• Focused on improving patient outcomes

• Addressing one or more stated Areas of Emphasis

• Advancing understanding, diagnosis or treatment of NF and schwannomatosis

Competitive applications are likely to include:

• Strong scientific rationale

• Significant translational potential

• Collaborative or multidisciplinary approaches

• Novel technologies or methodologies

• Preliminary and/or published data where required

Certain award mechanisms specifically encourage:

• High-risk, high-gain concepts

• Multi-investigator collaboration

• Data science approaches

• Open science participation

• Mentorship and workforce development in NF research

The solicitation also emphasizes research that could benefit Service Members, Veterans and the broader public.

Are there any restrictions I should know about?

Yes. Key restrictions include:

• Clinical trials are not allowed under the listed award mechanisms

• Several award mechanisms require preliminary and/or published data

• All applications require a pre-application submission through eBRAP before full application submission

• Multiple award mechanisms require submission of a letter of intent prior to full application submission

• Applications must conform to the final funding opportunity announcements posted on Grants.gov

The pre-announcement states that investigators should not construe the notice as an obligation or promise by the government.

How long will it take me to prepare an application?

Preparation timelines will vary significantly depending on the award mechanism.

Applicants pursuing:

• Multi-institutional collaborations

• Academy proposals

• Large-scale synergistic projects

• Open science options

should expect substantially longer preparation timelines due to coordination requirements, mentoring structures, collaborator commitments and supporting documentation.

Because all applications require pre-applications and several require letters of intent, applicants should begin planning before the official funding opportunity announcements are released.

How can BW&CO help?

BW&CO can support applicants with:

• Opportunity assessment and award mechanism selection

• Research strategy positioning

• Commercialization and impact narrative development

• Proposal writing and editing

• Collaboration structuring

• Project management and submission coordination

• Budget development support

• Grants.gov and eBRAP submission support

• Reviewer-style proposal feedback

Additional Resources

Review solicitation here.

CDMRP: Peer Reviewed Medical Research Program (PRMRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Peer Reviewed Medical Research Program (PRMRP) is a pre-announcement from the Department of Defense indicating substantial upcoming funding across a wide range of medical research topics relevant to military health. This is an early signal to begin preparing—applications are not yet open, and deadlines are not specified in this pre-announcement. Once released on Grants.gov, these opportunities will move quickly and require pre-applications or letters of intent.

This program supports everything from early-stage discovery through large-scale clinical trials, with awards ranging from $385,000 up to $20M+ depending on mechanism. Founders and research teams should begin aligning projects now to be competitive when announcements drop.

Pre-Applications are due on 7/16/26 and 7/23/26.

Full Applications are due between 7/30/26 and 9/22/26.

How much funding would I receive?

Funding varies significantly by award mechanism:

• Clinical Trial Award

  • Planning Phase: up to $800,000

  • Level 1: up to $6M

  • Level 2: up to $10M

  • Level 3: up to $20M

• Discovery Award

  • Up to $385,000

• Impact Award

  • Single PI: up to $2.8M

  • Partnering PI: up to $3.6M

• Lifestyle and Applied Health Research Award

  • Up to $4.2M

• Platform Clinical Translation Award

  • Up to $15M (with only $8M guaranteed from FY26 funds)

• Research Advancement Award

  • Up to $1.4M

• Technology/Therapeutic Development Award

  • Up to $5.6M

All amounts are total costs (direct + indirect).

What could I use the funding for?

Funding supports a broad spectrum of medical research aligned to congressionally mandated topic areas, including (not exhaustive):

• PTSD, traumatic brain injury, suicide prevention

• Burn pit exposure, respiratory health

• Rare diseases (e.g., Rett Syndrome, Fragile X, mitochondrial disease)

• Chronic conditions (e.g., diabetes-related areas not explicitly listed, IBD, fibromyalgia-related analogs where applicable)

• Women’s health (e.g., endometriosis, maternal mental health)

• Neurological and musculoskeletal conditions

Use cases depend on the mechanism:

• Discovery Award: High-risk, early-stage concepts (no preliminary data)

• Impact Award: Hypothesis-driven work with preliminary data

• Clinical Trial Award: Phase 0–3 trials

• Technology/Therapeutic Development: Translating preclinical work into products

• Platform Clinical Translation: Multi-indication platforms

• Lifestyle and Applied Health: Quality of life, behavioral, and applied interventions

Projects must align to at least one specified topic area.

Are there any additional benefits I would receive?

• Validation from the Department of Defense and CDMRP

• Access to non-dilutive capital at scale (up to $20M)

• Opportunity to support military-relevant health outcomes

• Structured pathways for clinical translation and regulatory readiness (e.g., IND/IDE planning support under Clinical Trial Award)

Additional benefits are not further specified in the pre-announcement.

What is the timeline to apply and when would I receive funding?

• Pre-Applications are due on 7/16/26 and 7/23/26.

• Full Applications are due between 7/30/26 and 9/22/26.

• Submission will require:

  • Pre-application (e.g., preproposal or letter of intent depending on mechanism)

  • Full application (often by invitation only)

• Periods of performance:

  • Range from 2 years to 4 years depending on mechanism

  • Planning phases up to 18 months

Exact award start timelines are not specified.

Where does this funding come from?

• FY26 Defense Appropriations Act

• Administered by:

  • Defense Health Agency (DHA) Research and Development

  • Medical Research and Development Command (MRDC)

  • Managed through the Congressionally Directed Medical Research Programs (CDMRP)

Who is eligible to apply?

• Independent investigators at all career levels

• Applies across all award mechanisms

No additional institutional, geographic, or organizational eligibility restrictions are specified in this pre-announcement.

What companies and projects are likely to win?

Based strictly on the solicitation:

• Projects that:

  • Align directly with congressionally mandated topic areas

  • Demonstrate clear relevance to military health

  • Show high impact and scientific merit

• Competitive profiles by mechanism:

  • Discovery: Bold, untested ideas without preliminary data

  • Impact: Strong preliminary data + near-term impact potential

  • Clinical Trial: Well-developed interventions ready for human testing

  • Technology/Therapeutic Development: Clear product-oriented outcomes

  • Platform Clinical Translation: Solutions addressing multiple topic areas

• Teams:

  • May include clinician researchers or industry partners (required in some partnering options)

Further selection criteria are not specified in this pre-announcement.

Are there any restrictions I should know about?

Key restrictions vary by mechanism:

• Clinical Trial Award

  • Cannot support preclinical research

  • Requires regulatory approvals (e.g., IND/IDE) where applicable

• Discovery Award

  • Cannot include preliminary data

  • Cannot support clinical trials

• Impact Award

  • Cannot support clinical trials

• Lifestyle and Applied Health Research Award

  • Cannot support animal studies

• Technology/Therapeutic Development Award

  • Cannot support clinical trials

• Research Advancement Award

  • Cannot support clinical trials

• All applications:

  • Must align to specified topic areas

  • Require pre-application submission (preproposal or LOI depending on mechanism)

How long will it take me to prepare an application?

Not explicitly specified, but based on required steps:

• Pre-application required (LOI or preproposal)

• Full applications often by invitation only

• Clinical trial applications may require:

  • Regulatory documentation (e.g., IND/IDE)

Exact preparation timelines are not specified in the pre-announcement.

How can BW&CO help?

BW&CO can support:

• Opportunity qualification against PRMRP mechanisms

• Topic area alignment and positioning

• Preproposal / LOI development

• Full application strategy and narrative development

• Clinical and product translation positioning

• Partnering strategy (e.g., clinician or industry PI alignment)

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Combat Readiness–Medical Research Program (CRRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Combat Readiness–Medical Research Program (CRRP) will fund innovative, high-impact research to improve Warfighter survivability and readiness, with a focus on trauma care and operational medical capabilities. This is a pre-announcement, giving advance notice so teams can prepare—the full funding opportunity with required deadlines has not yet been released.

Critically, application deadlines are not specified in this pre-announcement. Once released, the solicitation will include required pre-application and full application deadlines. Teams should begin preparing now, as this program uses a pre-application screening process with invitation-only full submissions.

How much funding would I receive?

• Maximum total funding: $2.45 million (total costs)

• Guaranteed funding from FY26: $1.45 million

• Remaining funding supports optional research efforts

• Period of performance:

  • Maximum total: 3 years

  • Base period: 2 years

  • Optional period: 1 year

What could I use the funding for?

Funding supports translational research in combat casualty care, including:

• Battlefield diagnostics, triage, and decision support tools

• Treatments to improve care delivery in:

  • Point of injury

  • Austere surgical/resuscitative environments

  • Prolonged casualty care

  • En route care

• Battlefield readiness solutions focused on pre-hospital and operational environments

Projects must be hypothesis-driven and supported by preliminary data and aim to move promising technologies toward real-world trauma care solutions.

Are there any additional benefits I would receive?

• Not specified in the pre-announcement.

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only

• The full funding opportunity will be posted on Grants.gov

• Pre-application submission is required via eBRAP

• Full applications are by invitation only

Application deadlines are not specified in this pre-announcement and will be provided when the official solicitation is released.

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by:

  • Congressionally Directed Medical Research Programs (CDMRP)

  • Under the Defense Health Agency (DHA) Research and Development – Medical Research and Development Command (MRDC)

Who is eligible to apply?

• Independent Investigators at all academic levels, or equivalent

No additional eligibility restrictions are specified.

What companies and projects are likely to win?

Projects most aligned with the program’s intent will:

• Address combat casualty care and operational medical challenges

• Demonstrate strong preliminary data

• Be translational—moving technologies toward real-world use

• Show potential to:

  • Improve survivability

  • Enable care closer to the point of injury

  • Inform trauma care guidelines

Are there any restrictions I should know about?

• Pre-application is required; full submission is invitation-only

• Applications must include preliminary data

• Research may include:

  • Animal models (allowed, not required)

  • Clinical research (allowed, not required)

  • Small-scale pilot clinical trials (optional, within performance period)

• Applications must conform to the final FOA once released

How long will it take me to prepare an application?

Not specified in the pre-announcement.

However, given the pre-application + invitation-only structure and requirement for preliminary data, teams should expect a multi-phase process and begin preparation early.

How can BW&CO help?

BW&CO can support across the full lifecycle:

• Positioning your technology against CRRP focus areas

• Developing a competitive pre-application strategy

• Translating technical work into clear, reviewer-aligned narratives

• Building a data-driven commercialization and impact story

• Managing submission through eBRAP and Grants.gov workflows

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Parkinson’s Research Program (PRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Parkinson’s Research Program (PRP) will fund innovative, high-impact research aimed at reducing risk, slowing progression, or easing symptoms of Parkinson’s disease. This is a pre-announcement, meaning you have time to prepare—but deadlines have not yet been released. Once funding opportunities are posted on Grants.gov, both pre-application and full application deadlines will be specified. Early preparation is critical to compete.

How much funding would I receive?

Funding depends on the award mechanism:

Early Investigator Research Award

• Funding Level 1:

  • Up to $300,000 total costs

  • Period of performance: 2 years

• Funding Level 2:

  • Up to $1,000,000 total costs

  • Period of performance: 2 years

Investigator-Initiated Research Award

• Up to $2,000,000 total costs

• Period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Funding supports Parkinson’s disease research aligned to one or more of the following focus areas:

• Disease heterogeneity and its impact on progression and outcomes

• Advanced in vitro model systems that reflect in vivo complexity

• Biomarkers and biological mechanisms tied to unmet medical needs

• Research addressing:

  • Non-motor symptoms (e.g., cognitive, sleep, psychiatric, pain)

  • Motor symptoms (e.g., tremor, gait, dyskinesia)

• Development and testing of interventions, including:

  • Biological, pharmacological, and non-pharmacological approaches

  • Surgical and non-surgical devices

  • Non-invasive CNS stimulation

Projects may range from laboratory models to studies involving human participants, depending on the mechanism.

Are there any additional benefits I would receive?

• Opportunity to work within a Department of Defense-funded research program

• Access to a program prioritizing clinically relevant, high-impact outcomes

• Optional Partnering PI structure (Investigator-Initiated Research Award) to support collaboration between two investigators

• Structured support for early-career researchers, including mentorship (for Funding Level 1)

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement; application deadlines are not yet specified

• Funding opportunity announcements will be posted on Grants.gov

• A pre-application is required via eBRAP before full submission

• Exact pre-application and full application deadlines will be included in the official announcements

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

Early Investigator Research Award

• Postdoctoral fellows, clinical fellows, or independent investigators within 10 years of degree or residency completion

• Eligibility must be verified via an institutional statement

Investigator-Initiated Research Award

• Independent investigators at all academic levels, or equivalent

What companies and projects are likely to win?

Competitive applications will:

• Address one or more of the specified focus areas

• Demonstrate high-impact potential and clinical relevance

• Include:

  • Strong mentorship and career development (early investigators)

  • Preliminary data where required

  • Rigorous, multidisciplinary approaches (Investigator-Initiated Research Award)

• Target unmet medical needs in Parkinson’s disease, especially across motor and non-motor symptoms

Are there any restrictions I should know about?

Early Investigator Research Award

• Clinical trials are not allowed

• Mentorship is required for Funding Level 1

• Preliminary data:

  • Not required for Level 1

  • Required for Level 2

Investigator-Initiated Research Award

• Preliminary data are required

• Clinical trials are allowed

General

• Pre-application submission via eBRAP is required

• Applications must follow final instructions in the official funding announcements

How long will it take me to prepare an application?

• Not specified in the pre-announcement

• However, the requirement for a pre-application and full application, along with preliminary data (for most mechanisms), indicates a moderate to high preparation effort

How can BW&CO help?

BW&CO can support you by:

• Interpreting the full funding announcement once released

• Positioning your project against PRP focus areas and review criteria

• Developing a compelling technical narrative and commercialization angle

• Managing pre-application and full submission workflows

• Supporting teaming strategies, including Partnering PI structures

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Duchenne Muscular Dystrophy Research Program (DMDRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Duchenne Muscular Dystrophy Research Program (DMDRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), will fund high-impact research to improve function and quality of life for individuals with Duchenne muscular dystrophy (DMD). This is a pre-announcement, meaning application deadlines are not yet specified. Founders and investigators should begin preparing now ahead of the official release on Grants.gov, where deadlines will be published.

How much funding would I receive?

Two award mechanisms are anticipated:

Idea Development Award

• Maximum funding: $500,000 in total costs

• Period of performance: 2 years

Clinical/Translational Research Award

Funding Level 1

• Single PI: $910,000 in total costs

• Partnering PI Option: $1 million in total costs

• Period of performance: 3 years

Funding Level 2

• Single PI: $1.75M in total costs

• Partnering PI Option: $1.9M in total costs

• Period of performance: 4 years

Total costs include direct and indirect costs.

What could I use the funding for?

Idea Development Award

• High-risk/high-reward research advancing understanding of DMD

• Development of macromolecular and cellular therapies targeting primary pathology

• Research must include preliminary data

• Cannot fund clinical trials or clinical trial aims

Clinical/Translational Research Award

• Translational research with near-term clinical impact

• Preclinical work supporting IND-enabling studies

• Clinical research including:

  • Real-world data or post-market studies

  • Combination or sequential therapy studies

  • Long-term safety and efficacy studies

  • Studies to improve care and quality of life

  • Clinical trial tools and outcome measures

  • Natural history studies for trial readiness

• Can include clinical trials, pilot trials, and readiness studies

• Must include preliminary data

Are there any additional benefits I would receive?

• Access to CDMRP-managed funding programs within the Defense Health Agency Research and Development ecosystem

• Optional Partnering PI structure for Clinical/Translational Research Awards to support collaboration between investigators

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only

• Pre-application and full application deadlines are not specified

• Deadlines will be released with the official funding opportunity announcements on Grants.gov

• A pre-application submission through eBRAP is required prior to full application submission

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

Idea Development Award

• Established independent investigators

• Early-stage investigators:

  • Within 10 years of first faculty appointment

  • Must not have previously received this award

• Transitioning investigators entering DMD from another field

• Must:

  • Be pursuing an active line of DMD research

  • Commit at least 10% effort annually

Clinical/Translational Research Award

• Independent investigators at all academic levels

• Optional Partnering PI must be:

  • Early-career (within 10 years), or

  • Established investigator from another field entering DMD

What companies and projects are likely to win?

• Projects focused on safe and effective macromolecular and cellular therapies addressing the primary pathology of DMD

• Research with clinical relevance and translational potential

• Studies that demonstrate impact across the lifespan, including:

  • Infants

  • Toddlers

  • Non-ambulatory individuals

• Applications supported by strong preliminary data

• High-risk/high-reward ideas (Idea Development Award) or near-term clinical impact (Clinical/Translational Award)

Are there any restrictions I should know about?

• Idea Development Award:

  • Cannot fund clinical trials or clinical trial aims

• All applications:

  • Must include preliminary data

  • Must align with specified focus areas

• Pre-application submission via eBRAP is required

• Applications must conform to final FOA requirements once released

How long will it take me to prepare an application?

• Not specified in the pre-announcement

• However, preparation should begin now given:

  • Required preliminary data

  • Mandatory pre-application step

  • Competitive, high-impact nature of the program

How can BW&CO help?

• Evaluate fit across Idea Development vs. Clinical/Translational tracks

• Shape your research into a CDMRP-aligned, reviewer-ready narrative

• Support Partnering PI strategy and positioning

• Develop compliant pre-applications and full submissions

• Maximize competitiveness for high-risk/high-reward and translational proposals

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

PASA has four live RFA 8 opportunities under the Study Research Planning Program (SRPP), and the first deadline comes fast: pre-applications are due 04/15/2026 across all four opportunities. Full applications are then due either 06/05/2026 or 06/17/2026 depending on the award type. In plain terms, this is a staged PASA funding cycle for teams working on drug discovery, pre-clinical animal research, human participant clinical trial planning, or expansion of previously funded PASA work. The planning award is for human participant clinical trial planning, the pre-clinical award is for animal research, the drug discovery award is for nonclinical discovery work, and the expansion award is only for current or previously funded PASA studies.

How much funding would I receive?

RFA 8a / Planning Award
Maximum Total Cost (Direct and Indirect): $150,000.
Period of Performance: 9-12 months.

RFA 8b / Pre-Clinical Award
The maximum total cost is not specified in the source materials I reviewed.
The period of performance is not specified in the source materials I reviewed.

RFA 8c / Drug Discovery Award
Maximum Total Cost (Direct and Indirect): $600,000.
Period of Performance: 24 months.

RFA 8d / Expansion Award
Maximum Total Cost (Direct and Indirect): $250,000-$750,000.
Period of Performance: 12-24 months.

What could I use the funding for?

RFA 8a / Planning Award
Use this for a specific compound or combination of compounds where you need a clinical implementation strategy to move toward FDA approval for ASUD treatment. PASA says the award supports development of a series of studies, the protocol for the first study, and related regulatory pathway work.

RFA 8b / Pre-Clinical Award
Use this for proof-of-principle pre-clinical animal research to determine which compounds are most appropriate for human research trials.

RFA 8c / Drug Discovery Award
Use this for proof-of-principle nonclinical drug discovery research to determine which compounds are most appropriate for later human research trials. The RFA says this can include computational-based analysis, including in silico and augmented intelligence research.

RFA 8d / Expansion Award
Use this only to continue or extend research that was previously funded by PASA. PASA says the expansion award may support drug discovery, pre-clinical, or clinical research, as long as it is the next step or an expansion on currently funded work.

Are there any additional benefits I would receive?

PASA says successful projects are conducted as part of PASA with PASA Management Core involvement. Across the RFAs, that support includes oversight and coordination, data repository functions, and analytic support. PASA’s support page also says PASA statisticians are available during proposal development to review or help develop power, sample size, and analytic plans, and that PASA-funded projects receive centralized management and statistical support after award.

For the Planning Award specifically, PASA says a productive award will yield a clinical implementation strategy, a protocol for the first study in the plan, and FDA approval or exemption for the plan and protocol.

What is the timeline to apply and when would I receive funding?

RFA 8a / Planning Award
Pre-application Due 04/15/2026.
Go/ No Go Response from PASA Management Core (for submission of full applications) 04/24/2026.
Full Application Due 06/05/2026.
Peer Review Process July 2026.
Consortium Steering Committee Review Mid-August 2026.
Notification of Award Recommendations August 2026.
Award Negotiations Begin September 2026.

RFA 8b / Pre-Clinical Award
Pre-application Due 04/15/2026.
Go/ No Go Response from PASA Management Core (for submission of full applications) 04/24/2026.
Full Application Due 06/17/2026.
Peer Review Process Ends July 2026.
Consortium Steering Committee Review Mid-August 2026.
Notification of Award Recommendations August 2026.
Award Negotiations Begin September 2026.

RFA 8c / Drug Discovery Award
Pre-application Due 04/15/2026.
Go/ No Go Response from PASA Management Core (for submission of full applications) 04/24/2026.
Full Application Due 06/17/2026.
Peer Review Process Ends July 2026.
Consortium Steering Committee Review Mid-August 2026.
Notification of Award Recommendations August 2026.
Award Negotiations Begin September 2026.

RFA 8d / Expansion Award
Pre-application Due 04/15/2026.
Go/ No Go Response from PASA Management Core (for submission of full applications) 04/24/2026.
Full Application Due 06/05/2026.
Peer Review Process Ends July 2026.
Consortium Steering Committee Review Mid-August 2026.
Notification of Award Recommendations August 2026.
Award Negotiations Begin September 2026.

The solicitations say award negotiations begin in September 2026. They do not specify an exact award date or disbursement date.

Where does this funding come from?

The solicitations and FAQ say PASA is funded by the Congressionally Directed Medical Research Programs (CDMRP) through the Alcohol and Substance Use Disorders Research Program (ASUDRP). The FAQ states PASA’s work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, managed by CDMRP under Awards W81XWH-15-2-0077, W81XWH-18-2-0044, W81XWH-22-2-0081 and HT94252520002.

Who is eligible to apply?

The FAQ says any institution can apply. It also says international submissions are allowed, more than one application from the same institution is allowed, and those applications are reviewed independently. Co-PIs are allowed. You do not need to already be associated with PASA to apply. For studies involving human participants, the FAQ says applications with Veteran’s Administration (VA) collaborators may be viewed more positively.

There is one major award-specific eligibility limit: RFA 8d / Expansion Award is only for current or previously funded PASA studies.

What companies and projects are likely to win?

The solicitations consistently favor projects that align closely with PASA’s goals and focus areas, address ASUD particularly but not limited to comorbid PTSD and other mental health conditions, and have strong potential to inform future clinical trials or improve pharmacotherapies.

• The strongest projects are likely to be those that:

  • show clear alignment with PASA strategic goals and focus areas;

  • present a strong research idea and clear impact;

  • demonstrate feasibility, appropriate budget, and strong team qualifications;

  • show how the work could support regulatory progression and future clinical trials; and

  • for planning awards and clinical work, show a path toward pharmaceutical collaboration or eventual marketing.

The FAQ says a commercial partnership is not required for funding, but for planning awards and clinical trials it is recommended, and a demonstrated relationship with a pharmaceutical company with a path to eventual marketing will be a factor in award selections.

For RFA 8d, the strongest projects are likely to be previously funded PASA studies that can clearly justify why the research is ready for the next phase and how the proposed work builds on prior PASA-funded results.

Are there any restrictions I should know about?

All four opportunities require a pre-application before a full application. PASA states that a “go” response from the PASA Management Core is required to proceed with the full application.

RFA 8d is limited to current or previously funded PASA work.

The FAQ says PASA RFA8 does not include the development and/or validation of animal models of disease.

For pre-clinical studies, PASA says most funded studies must be conducted in accordance with Good Laboratory Practice (GLP) requirements, though some basic science studies may not require GLP and PASA will make that determination in consultation with the PI.

For expansion awards, PASA says most studies must be conducted in accordance with GCP and/or GLP requirements.

Because PASA funding comes through CDMRP/ASUDRP, the solicitations say subaward funds will be subject to policies and restrictions based on that source of funding.

How long will it take me to prepare an application?

What is specified is the application structure. Each RFA requires a pre-application first, followed by a full application only if you receive a go decision. The pre-application is limited to four pages. Full applications then require multiple technical sections, budget materials, and supporting documentation. The planning award, pre-clinical award, drug discovery award, and expansion award each have different required components, so preparation time will depend on which RFA you target.

How can BW&CO help?

BW&CO can support across all phases of the CSO:

• Strategize the correct solicitation according to your project

• Help strategize on the nature and scope of the project

• Drafting the initial submission and managing the project of applying

• Increasing likelihood of success and saving time

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Toxic Exposures Research Program (TERP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is a pre-announcement for the FY26 Toxic Exposures Research Program (TERP), signaling upcoming funding opportunities but no application deadline is provided at this stage. Founders and researchers should begin planning now, as future funding opportunity announcements will include required pre-application and full application deadlines once released on Grants.gov.

The program will fund high-impact research with clinical relevance focused on preventing, diagnosing, and treating conditions related to military-related toxic exposures. Awards span clinical trials, translational research, and investigator-initiated studies.

How much funding would I receive?

Funding depends on the award mechanism:

• Clinical Trial Award

  • Up to $4.5 million total costs

  • Maximum 4 years

• Translational Research Award

  • Up to $1.5M total costs

  • Maximum 3 years

• Investigator-Initiated Research Award

  • Up to $800,000 total costs

  • Maximum 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Funding supports research aligned with at least one program goal:

• Predict and prevent

  • Monitoring and prevention strategies

  • Risk factor identification

  • Multigenerational and reproductive effects

  • Exposure tracking technologies

• Diagnose

  • Biomarkers and diagnostics

  • Disease progression understanding

  • Multi-exposure and stressor interactions

• Treat

  • Therapeutics and interventions

  • Preclinical models (non-clinical trial mechanisms only)

  • Strategies to reduce symptoms and disease progression

Projects must also address at least one topic area:

• Neurotoxin Exposure

• Gulf War Illness and Its Treatment

• Airborne Hazards and Burn Pits

• Other military-related toxic exposures (e.g., pesticides, organophosphates, metals)

Are there any additional benefits I would receive?

• Partnering PI option available for Clinical Trial and Translational Research Awards (two PIs, separate awards)

• Strong encouragement for:

  • Collaboration with military and/or VA researchers and clinicians

  • Inclusion of a clinician on the team

  • Participation of a military or Veteran consumer (required/encouraged depending on mechanism)

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement

• Application deadlines are not specified

• Future funding opportunity announcements will include:

  • Pre-application (required) via eBRAP

  • Full application (by invitation only)

Additional timing details:

• Clinical trials are expected to begin within 12 to 18 months of the award date

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

• Independent investigators at all career levels

No additional eligibility restrictions are specified.

What companies and projects are likely to win?

Projects that:

• Address at least one program goal and one topic area

• Demonstrate clinical relevance and impact on patient outcomes

• Include preliminary data (required across all mechanisms)

• Align with:

  • Prevention, diagnosis, or treatment of toxic exposure effects

• Incorporate:

  • Collaboration with military/VA stakeholders

  • Clinical expertise

  • Consumer (Veteran/military) input where encouraged

Clinical Trial Awards specifically favor:

• Trials ready for rapid implementation

• Studies evaluating products, drugs, biologics, devices, or clinical approaches

Are there any restrictions I should know about?

• Preproposal is required; full application is by invitation only

• All applications must include preliminary data

Mechanism-specific restrictions:

• Clinical Trial Award

  • Must include a clinical trial

  • Cannot include preclinical studies (including animal research)

• Investigator-Initiated Research Award

  • Cannot include clinical trials

• Translational Research Award

  • Cannot include clinical trials

How long will it take me to prepare an application?

Not specified in the pre-announcement.

However:

• A pre-application is required first, followed by an invited full application

• Investigators are encouraged to begin planning now due to the staged process

How can BW&CO help?

BW&CO can support you by:

• Interpreting TERP priorities and aligning your project to program goals and topic areas

• Structuring a competitive preproposal to secure invitation

• Developing a full application strategy grounded in clinical impact and reviewer expectations

• Positioning collaborations with military, VA, and clinical stakeholders

• Ensuring compliance with CDMRP and eBRAP submission requirements

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Military Burn Research Program (MBRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Military Burn Research Program (MBRP) will fund innovative, high-impact research focused on military-relevant burn trauma care in austere, combat environments. This is an early pre-announcement, giving teams time to prepare ahead of formal release on Grants.gov.

Application deadlines are not yet specified — they will be provided when the official funding opportunity announcements are released. Founders and researchers should begin planning now, as all mechanisms require a preproposal and are invitation-only for full applications.

How much funding would I receive?

Funding varies by award mechanism:

• Discovery Award

  • Up to $200,000 total costs

  • Up to 2 years

• Patient-Centered Research Award (PCRA)

  • Single PI: Up to $1.6 million total costs

  • Mentorship Option: Up to $1.8 million total costs

  • Up to 4 years

• Technology/Therapeutic Development Award (TTDA)

  • Single PI: Up to $1.6 million total costs

  • Mentorship Option: Up to $1.8 million total costs

  • Up to 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Funding must support research aligned to combat-relevant burn care, including:

• Cold injury triage, treatment, and prevention

• Acute burn care in combat settings

• Prevention, assessment, or treatment of burn-related complications:

  • Fluid resuscitation issues

  • Endotheliopathy

  • Sepsis

  • Inhalation injuries

  • Fungal infections

  • Hypermetabolism

• Early interventions to reduce long-term complications (e.g., chronic pain, neuropathy, pruritus)

By mechanism:

• Discovery Award: Early-stage, exploratory, non-clinical research (no clinical trials)

• PCRA: Clinical research and clinical trials only

• TTDA: Product-focused development (devices, drugs, or clinical practice tools), no clinical trials

Are there any additional benefits I would receive?

• Optional Mentorship Option (PCRA and TTDA) to support collaboration between senior and junior researchers

• Access to CDMRP-managed funding infrastructure

• Opportunity to build solutions for military and battlefield healthcare applications

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only

• Application deadlines are not yet specified

• Once released:

  • Pre-applications must be submitted via eBRAP

  • Full applications are invitation-only following preproposal review

• Timing for award decisions and funding is not specified

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

• Discovery Award: Investigators at all academic levels (or equivalent)

• PCRA & TTDA: Independent investigators at all academic levels (or equivalent)

No additional eligibility restrictions are specified.

What companies and projects are likely to win?

Competitive applications will:

• Directly address combat-relevant burn care challenges

• Focus on austere, resource-limited, battlefield environments

• Show:

  • Strong scientific rationale

  • Clear study design and analysis plan

  • Alignment with one or more listed focus areas

By mechanism:

• Discovery: Novel, early-stage ideas with potential future impact

• PCRA: Clinically actionable research with preliminary data

• TTDA: Clear path to a tangible product, supported by proof of concept

Are there any restrictions I should know about?

• Preproposal required; full application is invitation-only for all mechanisms

• Mechanism-specific restrictions:

  • Discovery: No clinical trials

  • PCRA: No preclinical or animal research

  • TTDA: No clinical research or clinical trials

• Preliminary data:

  • Required for PCRA and TTDA

  • Optional for Discovery

• All applications must follow final FOA requirements once released

How long will it take me to prepare an application?

• Not explicitly specified

• However, applicants should plan for:

  • Preproposal development

  • Invitation-based full application

• Given the structure, preparation will likely require multiple stages, but exact timelines are not specified

How can BW&CO help?

BW&CO can support you across both stages:

• Identify the best-fit mechanism (Discovery vs. PCRA vs. TTDA)

• Shape your concept to align with combat burn priorities

• Develop a competitive preproposal strategy

• Build a full application (if invited), including:

  • Technical narrative

  • Commercialization or translation framing (for TTDA)

  • Clinical positioning (for PCRA)

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Joint Warfighter Medical Research Program (JWMRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Joint Warfighter Medical Research Program (JWMRP) FY26 funding opportunity is expected to support continuation of late-stage medical R&D projects that address critical Department of War (DOW) capability gaps. This is not for new ideas—only existing, previously funded projects that are close to delivering impact are eligible.

This is a pre-announcement, and full funding opportunity announcements (FOAs) with deadlines will be posted on Grants.gov. The application deadline is not specified in this pre-announcement. Founders should begin preparing now to align with the anticipated requirements and pre-application process.

How much funding would I receive?

Two award options are available:

• MMRDA

  • Maximum funding: $1.25M (total costs)

  • Period of performance: Up to 3 years

• MMRDA – Clinical Research/Trial Option

  • Maximum funding: $3M (total costs)

  • Period of performance: Up to 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Funding is strictly for continuation of existing projects, including:

• Late-stage preclinical studies

• Late-stage technology development

• Technology demonstration

• Translational research

• Clinical research and trials (under Clinical Research/Trial Option)

• Development of:

  • Pharmaceutical or biologic candidates

  • Medical devices

  • Medical technologies

Projects must address at least one focus area:

• Non-vaccine infectious disease prevention/treatment (excluding malaria)

• Hemorrhage mitigation and trauma resuscitation

• Injury from temperature extremes

• Musculoskeletal injury (MSKI) treatment and prevention

• Radiation exposure countermeasures (excluding cytokines)

Are there any additional benefits I would receive?

Not specified in the pre-announcement.

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only

• Full FOAs will be released on Grants.gov

• A pre-application is required via eBRAP

• Full applications are by invitation only

The application deadline is not specified in this pre-announcement.
Award timing is not specified.

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

• Extramural and intramural applicants

• Independent investigators at all academic levels (or equivalent)

Additional required eligibility conditions:

• Must have previously received DOW core or congressionally directed funding

• Must propose a continuation of the same research concept

• Projects must already be at Technology Readiness Level (TRL) 5 or above

What companies and projects are likely to win?

Based on stated requirements, competitive projects will:

• Be continuations of previously funded DOW projects

• Be near deployment or impact (TRL 5+)

• Address one or more JWMRP focus areas

• Demonstrate clear progress toward military medical capability gaps

• Be positioned for translation, demonstration, or clinical validation

Are there any restrictions I should know about?

Yes—this program is highly restrictive:

• No new projects allowed

• No basic research allowed

• Must be a continuation of prior DOW-funded work

• Must meet TRL 5 or higher requirement

• Pre-application is mandatory

• Full application is by invitation only

• Must align with at least one focus area

How long will it take me to prepare an application?

Not specified in the pre-announcement.

How can BW&CO help?

BW&CO supports companies pursuing defense innovation and CSO opportunities like this one.

We help by:

• Assess whether your prior DOW-funded project qualifies

• Position your continuation strategy to align with JWMRP focus areas

• Develop a compelling pre-application for eBRAP

• Prepare a full application (if invited) that emphasizes:

  • Translational readiness

  • Military relevance

  • Programmatic alignment

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Bone Marrow Failure Research Program (BMFRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Bone Marrow Failure Research Program (BMFRP) pre-announcement is live. This is an early signal to start preparing now—formal funding opportunities will follow on Grants.gov. There is no application deadline specified in this pre-announcement, and investigators should not wait for the full announcement to begin planning.

This program will fund research addressing bone marrow failure (BMF), with a focus on treatments, disease understanding, and community resources. Pre-announcements like this are your only early advantage—teams that move now are significantly more competitive once the FOA drops.

How much funding would I receive?

Funding varies by award mechanism:

• Idea Development Award

  • Maximum: $800,000 total costs

  • Period of performance: Up to 3 years

• Investigator-Initiated Research Award

  • Maximum: $1,250,000 total costs

  • Period of performance: Up to 3 years

• Resource Development Award

  • Maximum: $1,250,000 total costs

  • Period of performance: Up to 2 years

Total costs include direct and indirect costs.

What could I use the funding for?

Projects must align to at least one required FY26 BMFRP focus area:

• Develop durable resources for the bone marrow failure research community

• Find effective BMF treatments and cures

• Understand the causes and progression of BMF diseases

Each award mechanism has specific intent:

• Idea Development Award: Early-stage, hypothesis-driven research with translational potential

• Investigator-Initiated Research Award: More mature research building on prior findings with strong preliminary data

• Resource Development Award: Creation of shared tools, datasets, or infrastructure for the BMF community

Are there any additional benefits I would receive?

• Partnering Principal Investigator option available under the Investigator-Initiated Research Award

• Separate review tracks for early-career vs. established investigators (Idea Development Award)

• Encouragement for correlative studies tied to existing clinical trials/studies

• Emphasis on translational potential, including work supporting an Investigational New Drug (IND) application

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: March 10, 2026

• Pre-application required via eBRAP before full application

• Full applications are invitation-only after preproposal review

• Funding opportunity announcements will be posted on Grants.gov

• Application deadline: Not specified in the pre-announcement

• Award timing: Not specified in the pre-announcement

Where does this funding come from?

• FY26 Defense Appropriations Act

• Managed by the Congressionally Directed Medical Research Programs (CDMRP)

• Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Idea Development Award:

  • Early-Career Investigators (<10 years from first appointment)

  • Established Investigators (≥10 years from first appointment)

• Investigator-Initiated Research Award:

  • Independent investigators at all career levels

• Resource Development Award:

  • Independent investigators at all career levels

Additional institutional or organizational eligibility is not specified in the pre-announcement.

What companies and projects are likely to win?

Based on required criteria:

• Projects must align tightly with one of the FY26 BMFRP focus areas

• Strong scientific rationale and testable hypothesis (Idea Development Award)

• Preliminary data required (Investigator-Initiated and Resource Development Awards)

• Clear translational impact and potential to advance patient care

• Resource proposals must demonstrate data/sample access and a clear distribution plan

Are there any restrictions I should know about?

• Preproposal required; full applications are invitation-only

• Clinical trials are not allowed under any mechanism

• Applications must align to specified focus areas

• Resource Development Award is limited to the resource-focused track only

• The pre-announcement does not obligate the government to fund awards

How long will it take me to prepare an application?

The structure implies:

• Initial preproposal preparation (required for all mechanisms)

• Full proposal only if invited

The pre-announcement is explicitly intended to give teams time to begin planning ahead of the formal deadlines.

How can BW&CO help?

BW&CO supports companies pursuing defense innovation and CSO opportunities like this one.

We help by:

• Position your project against the three distinct award mechanisms

• Build a preproposal strategy that secures invitation to full application

• Shape your narrative around CDMRP review expectations and translational impact

• Align your work to IND-enabling or high-impact outcomes where applicable

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Epilepsy Research Program (ERP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Epilepsy Research Program (ERP) from the Congressionally Directed Medical Research Programs (CDMRP), managed by the Defense Health Agency Research and Development – Medical Research and Development Command, is expected to fund innovative research focused on post-traumatic epilepsy (PTE) and related comorbidities.

The program’s goal is to improve quality of life for Service Members, Veterans, caregivers, and the broader epilepsy community by advancing understanding of the biological mechanisms, epidemiology, progression, and treatment of PTE.

This announcement is a pre-announcement, meaning investigators should begin preparing ideas now. Application deadlines have not yet been released. The official Funding Opportunity Announcements (FOAs), which will include submission deadlines, will be posted on Grants.gov.

How much funding would I receive?

Funding amounts depend on the award mechanism.

• Idea Development Award

  • Maximum funding: $1 million total costs

  • Maximum period of performance: 3 years

• Leveraging Research Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

• Research Partnership Award

  • Maximum funding: $2 million total costs

  • Maximum period of performance: 3 years

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Maximum funding: $1.6 million total costs

  • Maximum period of performance: 4 years

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

ERP funding supports research designed to advance understanding of post-traumatic epilepsy (PTE) and related conditions. Applications should address at least one of the program’s focus areas:

Markers and Mechanisms of PTE

• Identification of biomarkers predicting epilepsy development

• Research into biological mechanisms that could prevent epileptogenesis or seizure activity

Epidemiological Characterization of PTE

• Identifying predictors of epilepsy development

• Studying patient outcomes such as latency to epilepsy onset, comorbidities, and mortality

• Measuring impacts on quality of life for patients and caregivers

Longitudinal Studies of PTE Progression

• Tracking disease progression over time

• Evaluating treatment outcomes and quality of care

• Studying interactions between epilepsy and comorbid conditions such as psychiatric disorders, cognitive deficits, sleep disorders, and fatigue

Innovative Research Tools and Technologies

• Artificial intelligence or bioinformatics tools

• Clinical databases and advanced device technologies for seizure detection and diagnosis

• Models for studying post-traumatic epilepsy

• Tools enabling future clinical trials

Are there any additional benefits I would receive?

Some award mechanisms provide benefits beyond funding.

For example:

• Research Partnership Award

  • Supports collaborative research between two named Principal Investigators

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Provides funding to lead a virtual research center

  • Includes responsibilities such as mentoring investigators and facilitating collaboration

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Supports early-career researchers or investigators new to the PTE field

  • Includes mentorship and career development within a collaborative research environment

What is the timeline to apply and when would I receive funding?

The process will include:

• Pre-application submission through eBRAP

• Pre-applications will be Letters of Intent

• Full applications will follow the requirements outlined in the final FOAs on Grants.gov

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, which provides funding for the Epilepsy Research Program (ERP).

The program is administered by:

• Congressionally Directed Medical Research Programs (CDMRP)

• Defense Health Agency Research and Development – Medical Research and Development Command

ERP focuses on research that benefits Service Members, Veterans, caregivers, and the broader epilepsy community.

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Idea Development Award

  • Independent investigators at any career level may serve as Principal Investigator

• Leveraging Research Award

  • Independent investigators at any career level may serve as Principal Investigator

• Research Partnership Award

  • Two named Principal Investigators who are independent investigators at any career level

• Virtual P-TERC Leadership Award

  • Director and Deputy Director must be independent investigators with:

    • Strong history of PTE research funding

    • Peer-reviewed publications

    • Mentorship experience

• Virtual P-TERC Faculty Award

  • Early-career investigators or investigators new to the PTE field

What companies and projects are likely to win?

ERP prioritizes research that:

• Advances understanding of post-traumatic epilepsy and associated comorbidities

• Improves quality of life for Service Members, Veterans, and caregivers

• Demonstrates innovation or high creativity

• Challenges existing research paradigms

• Leverages existing datasets, cohorts, or research infrastructure

• Includes strong collaborations where appropriate

Are there any restrictions I should know about?

Key requirements include:

• Pre-applications must be submitted through eBRAP

• All pre-applications are Letters of Intent

• Full applications must follow the requirements of the final Funding Opportunity Announcements on Grants.gov

• Applications must align with the ERP’s focus areas on post-traumatic epilepsy

How long will it take me to prepare an application?

Preparation time will depend on the complexity of the project and research team.

Typical CDMRP submissions involve:

• A Letter of Intent (pre-application)

• A full application including research plan, budget, and supporting documentation

Because official deadlines have not yet been released, investigators should begin developing project concepts now so they are ready once the FOAs are posted.

How can BW&CO help?

BW&CO supports companies and research teams pursuing CDMRP and other federal research funding by:

• Identifying the most competitive award mechanism

• Developing a compelling proposal narrative aligned with program priorities

• Structuring the research plan and milestones

• Coordinating multi-institution collaborations

• Managing the full submission process through eBRAP and Grants.gov

Our team has extensive experience helping applicants pursue defense health and biomedical research funding.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Alzheimer’s Research Program (AZRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Alzheimer’s Research Program (AZRP) is expected to release funding opportunities through the Congressionally Directed Medical Research Programs (CDMRP) to support impactful research addressing Alzheimer’s disease and Alzheimer’s disease–related dementias (AD/ADRD).

06-22-2026 - (Pre-application - Pre-Proposal)
09-24-2026 - (Application)

The program’s mission is to fund solution-oriented research that improves quality of life for people living with Alzheimer’s disease and related dementias, including Service Members, Veterans, their Families, and the general public.

Congress appropriated $15.0 million for the FY26 Alzheimer’s Research Program.

The FY26 AZRP is expected to support research that improves diagnosis, prevention, risk reduction, and quality of life for individuals affected by AD/ADRD.

How much funding would I receive?

Funding depends on the award mechanism.

Transforming Care Award

• Maximum funding: $1.6M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.8M total costs

• Maximum period of performance: 4 years

Transforming Diagnosis Award

• Maximum funding: $1.5M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.7M total costs

• Maximum period of performance: 4 years

Transforming Research Award

• Maximum funding: $1M total costs

• Maximum period of performance: 3 years

What could I use the funding for?

Funding supports non-incremental, solution-focused research addressing Alzheimer’s disease and related dementias (AD/ADRD).

The allowable research depends on the mechanism.

Transforming Care Award

Supports well-designed non-incremental clinical research or clinical trials in dementia care that provide solutions for individuals living with AD/ADRD.

Projects may address:

• Care interventions

• Strategies or technologies for dementia care

• Tools that improve daily living and support systems

• Approaches that reduce caregiver burden and stress

• Methods that improve quality of life for individuals with dementia

Applications are encouraged to prioritize both:

• Individuals living with AD/ADRD

• Their care partners

Transforming Diagnosis Award

Supports solutions-oriented research addressing barriers to diagnosis, disease monitoring, or prognosis.

Barriers may include:

• Diagnostic technologies

• Cost barriers

• Access to diagnostic tools

• Clinical implementation challenges

• Biomarker validation

• Disease monitoring methods

• Lack of longitudinal data for prediction or prognosis

Research may include:

• Prospective human subject recruitment

• De-identified human samples, specimens, or datasets

Transforming Research Award

Supports research that reduces risk and prevents the development of AD/ADRD.

Applications must address one of two focus areas:

Risk factor knowledge

• Identification or validation of risk or protective factors

• Environmental, epigenetic, genetic, lifestyle, or occupational risks

Risk reduction solutions

• Non-pharmacological methods

• Technologies

• Prevention strategies that reduce risk of AD/ADRD

The program encourages studies leveraging existing cohorts or datasets, including cohorts 65 years or younger.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional non-funding benefits.

However, CDMRP programs typically provide:

• Access to a two-tier review system combining scientific peer review and programmatic review to ensure scientific merit and mission relevance.

• Opportunities to collaborate with researchers, clinicians, and community stakeholders affected by the disease.

What is the timeline to apply and when would I receive funding?

06-22-2026 - (Pre-application - Pre-Proposal)
09-24-2026 - (Application)

Where does this funding come from?

This funding comes from the Congressionally Directed Medical Research Programs (CDMRP) within the Department of Defense.

Key facts:

• Funding was appropriated through the Consolidated Appropriations Act, 2026.

• CDMRP manages biomedical research programs supporting the health of Service Members, Veterans, their Families, and the American public.

Who is eligible to apply?

Detailed eligibility criteria will be provided in the official Funding Opportunity Announcements.

What companies and projects are likely to win?

The AZRP supports projects that:

• Address critical needs in Alzheimer’s disease and related dementias

• Deliver solution-oriented outcomes

• Improve diagnosis, prevention, or patient quality of life

• Demonstrate clear relevance to Service Members, Veterans, their Families, or the broader public

Projects that show strong scientific merit and mission relevance are prioritized through CDMRP’s two-tier review process.

Are there any restrictions I should know about?

Restrictions and requirements are not specified in the pre-announcement.

These details—including allowable costs, research scope limitations, and regulatory requirements—will be defined in the full Funding Opportunity Announcements.

How long will it take me to prepare an application?

The preparation timeline is not specified in the pre-announcement.

CDMRP programs often use a two-stage process that may include:

• Pre-application submission

• Invitation to submit a full application

However, the specific process for FY26 AZRP is not specified in the pre-announcement.

How can BW&CO help?

BW&CO supports teams pursuing CDMRP funding by:

• Assessing project fit with the AZRP mission and research priorities

• Developing a competitive technical narrative

• Structuring proposals to align with CDMRP review criteria

• Managing submission strategy, compliance, and timeline

• Coordinating collaborators, investigators, and supporting documentation

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Autism Research Program

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Autism Research Program (ARP) from the Congressionally Directed Medical Research Programs (CDMRP) will fund innovative, high-impact research with clinical relevance that improves outcomes for individuals with autism and their families. The program released this pre-announcement to allow investigators time to plan proposals before the formal Funding Opportunity Announcements (FOAs) are released.

The FY26 ARP was funded through the FY26 Defense Appropriations Act. Investigators should begin preparing now because the program will require a pre-application before submission of a full proposal once the FOAs are released.

Application deadline: The deadline is not specified in the solicitation. Deadlines will be published in the FY26 ARP funding opportunity announcements when they are released on Grants.gov.

How much funding would I receive?

Funding depends on the specific award mechanism.

Career Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Clinical Trial Award

• Maximum funding: $1.5 million total costs

• Maximum period of performance: 4 years

Clinical Trial Award – Nested Early-Career Investigator Option

• Maximum funding: $1.75 million total costs

• Maximum period of performance: 4 years

Idea Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Each mechanism supports different types of autism research.

Career Development Award

• Supports early-career independent investigators or established investigators transitioning into autism research.

• Projects must pursue research with the potential to have a major impact on autism.

• Supported activities include:

  • Innovative, high-impact research ideas

  • Early-phase, proof-of-principle clinical trials

• Preliminary data is required.

Clinical Trial Award

• Supports research with the potential to have a major impact on the treatment and/or management of autism.

• Projects must involve clinical trials supported by preliminary data.

Clinical Trial Award – Nested Early-Career Investigator Option

• Allows a senior investigator (initiating PI) to collaborate with a young investigator.

• Supports the development of investigators pursuing careers in autism clinical trial research.

Idea Development Award

• Supports innovative, high-impact ideas that advance understanding of autism and lead to improved outcomes.

• Includes a Partnering PI Option allowing collaboration between two investigators.

• Clinical trials are not allowed under this mechanism.

All mechanisms require preliminary data relevant to the proposed project.

Are there any additional benefits I would receive?

The program includes several structural benefits:

• Career Development Award supports the transition of researchers into the autism field.

• Clinical Trial Award – Nested Early-Career Investigator Option provides structured development for young investigators.

• Idea Development Award – Partnering PI Option encourages collaboration between investigators.

These structures are designed to expand the autism research workforce and accelerate impactful research.

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: March 2, 2026

• Funding Opportunity Announcements (FOAs) will be posted on Grants.gov.

• Pre-application submission through eBRAP is required before submitting a full application.

• Application submission is by invitation only after review of the pre-application.

• Pre-application and full application deadlines are not specified in the pre-announcement.

• Funding start dates are not specified in the pre-announcement.

Where does this funding come from?

Funding for the program comes from the FY26 Defense Appropriations Act and is administered by the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development – Medical Research and Development Command.

The program is part of the Department of Defense’s Autism Research Program (ARP).

Who is eligible to apply?

Eligibility varies by mechanism.

Career Development Award
Applicants must:

• Be independent investigators at or below the level of Assistant Professor, or equivalent,

  or

• Be established investigators in a field other than autism at or above the level of Assistant Professor seeking to transition into autism research.

Additional requirements:

• Must not have previously received a Career Development Award (or equivalent) from any CDMRP program or other federal agency.

• Must not have received more than $250,000 in total direct costs for previous or concurrent autism research as a PI of federally or privately funded non-mentored peer-reviewed grants.

• Must hold a Ph.D., M.D., M.D./Ph.D., or equivalent at the time of pre-application submission.

• Must not be a graduate student, postdoctoral fellow, or other mentored researcher.

Clinical Trial Award

• Independent investigators at any career level.

Clinical Trial Award – Nested Early-Career Investigator Option
Young investigator must:

• Be currently in postdoctoral training or have completed postdoctoral training.

• Be no more than 7 years from receipt of a terminal degree.

• Commit at least 50% time to the project.

Idea Development Award

• Independent investigators at any career level.

What companies and projects are likely to win?

Based on the pre-announcement, competitive applications will likely:

• Propose innovative, high-impact research addressing autism

• Demonstrate strong preliminary data

• Show potential for major impact on understanding, treatment, or management of autism

• Align with the goals of the specific award mechanism

• For collaboration options, demonstrate meaningful partnerships between investigators

Applications must clearly demonstrate scientific merit and potential impact.

Are there any restrictions I should know about?

Key restrictions include:

• Pre-application submission through eBRAP is required before submitting a full application.

• Full applications are submitted by invitation only.

• Preliminary data is required for all mechanisms.

• Idea Development Award applications cannot support clinical trials, including a clinical trial aim.

• Career Development Award applicants must meet prior funding and career stage restrictions.

All applications must conform to the final Funding Opportunity Announcements posted on Grants.gov.

How long will it take me to prepare an application?

The solicitation does not specify preparation time.

However, because the ARP uses a two-stage process (pre-application followed by invitation-only full application), applicants typically need time to:

• Prepare a competitive pre-proposal

• Develop preliminary data and a detailed research plan

• Assemble collaborators and institutional approvals

Investigators are encouraged to begin planning early before FOAs are released.

How can BW&CO help?

BW&CO can support applicants throughout the ARP application process, including:

• Evaluating project fit with ARP mechanisms

• Developing a competitive proposal strategy

• Structuring impact-focused research narratives

• Managing the pre-application and full application process

• Preparing supporting documents and compliance materials

• Coordinating multi-investigator collaborations

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Synthetic Alkali Atom Vapor Density for Atom-Based Sensors - SBIR Topic DON26BZ01-NV037

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Simplify the thermal management of practical atom-based quantum sensors based on alkali atoms by creating a passive atom source operated at thermal equilibrium based on a synthetic alkali vapor density for rubidium or cesium atoms.

Description:

Quantum sensors based on atoms offer the opportunity to produce measurements with excellent sensitivity or long-term stability, making them attractive use in atomic clocks, magnetometers, or inertial sensors. In these sensors, the atomic vapor represents the sensing media where variations in signal magnitude from fluctuations in atom number can lead to instability or loss of sensitivity. Maintaining consistent signal throughout environmental conditions represents one of several key design criteria for atom-based sensors for use outside the laboratory.

Many atom-based sensors rely on heavy alkali atoms, specifically rubidium and cesium. This is because of the simplified, hydrogen-like energy level structure, the availability of narrow-linewidth semiconductor diode lasers on the relevant D1 (795/895 nm) and D2 (780/852 nm) transitions, the accessibility of commercial microwave electronics at the 3-10 GHz hyperfine splittings, and the ease of production of vapor phase atoms at modest temperatures. The temperature dependence of the alkalis [Ref 1] leads to thermal stabilization at 80-130°C (ideal for vapor cells at 10e12-10e14/cc) or closer to room temperature (ideal for atom trapping at 10e8-10e10/cc). These temperatures rarely align with thermal profiles of other aspects of the system, requiring additional design at the expense of size, weight, and power (SWaP).

Active approaches to alkali regulation have been demonstrated to manipulate the vapor to a non-equilibrium state. These approaches involve forced chemical reactions, intercalated graphite, alkali impregnated materials glasses [Refs 2,3]. In each case, a feedback loop must respond to measurements of the vapor density, leading to extra sensor complexity.

An equilibrium vapor density represents the simplest atom source which can be synthetically adjusted to an elevated temperature through a mixture [Ref 4]. Here, a primary species mixed with a secondary species reduces the equilibrium vapor density of both species by the mixing ratio following Raoult’s Law [Ref 5]. Selecting a lower vapor density secondary species limits the negative impact of additional atom-atom collisions. Such an approach can be applied to laser-cooled systems in addition to vapor cells to enable equilibrium operation at elevated system temperature, providing tight thermal regulation at low power.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

CDMRP: FY26 Lung Cancer Research Program (LCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now to prepare for the FY26 Lung Cancer Research Program (LCRP) funding opportunities — anticipated to open on Grants.gov imminently. This chance is critical for investigators aiming to drive innovative, high-impact research that will eradicate deaths and suffering from lung cancer, with a focus on outcomes that benefit Service Members, Veterans, their families, and the general public. Exact pre-application and application deadlines will be posted in the final NOFOs on Grants.gov when released.

Pre-Applications are due on 6/23/26 and 8/18/26.

Full Applications are due on 9/02/26.

How much funding would I receive?

Award amounts for the FY26 LCRP are specified by mechanism:

• Idea Development Award: Up to $800,000 total costs over 3 years.

• Translational Research Award (Level 1): Up to $1.35M total costs over 3 years.

• Translational Research Award (Level 2 – Clinical Trial Option): Up to $1.85M total costs over 4 years.

• Patient-Centered Outcomes and Survivorship Award: Up to $975,000 total costs over 3 years.

What could I use the funding for?

Funding supports research in the following Areas of Emphasis:

• Biology & Etiology: Mechanisms of lung cancer initiation and progression.

• Prevention & Risk Reduction: Innovative prevention and recurrence reduction strategies.

• Detection, Diagnosis & Surveillance: Improved early detection and disease monitoring.

• Treatment & Prognosis: Novel treatments, biomarkers, and metastasis management.

• Health Outcomes & Survivorship: Survivorship quality of life, comorbidity impacts, and disparities reduction.

Each mechanism has specific focus and eligibility criteria detailed in the forthcoming NOFOs.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional benefits (e.g., data resources or training support). These may be described in the final funding opportunity announcements.

What is the timeline to apply and when would I receive funding?

• Pre-Applications are due on 6/23/26 and 8/18/26.

• Full Applications are due on 9/02/26.

Where does this funding come from?

Funding arises from the FY26 Defense Appropriations Act and is administered through the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development.

Who is eligible to apply?

Eligibility (e.g., investigator types, institution requirements) will be outlined in the final NOFOs. The pre-announcement does not include full eligibility details.

What companies and projects are likely to win?

Applicants are more competitive if they:

• Align tightly with one or more Areas of Emphasis.

• Demonstrate innovation and potential clinical impact.

• Address relevance to military health (e.g., Veteran populations, exposures).

Are there any restrictions I should know about?

• Some mechanisms (e.g., Idea Development) do not allow clinical trials.

• Specific restrictions and requirements will be in the NOFOs once released.

How long will it take me to prepare an application?

Preparation time depends on the mechanism, project maturity, and whether preliminary data or partnerships are needed. Start planning now to align with the mechanisms and Areas of Emphasis.

How can BW&CO help?

BW&CO can help you:

• Decode the final NOFO requirements.

• Align your research strategy to maximize impact.

• Draft and polish pre-applications/ applications.

• Manage submission logistics and compliance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Orthopaedic Research Program (ORP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Orthopaedic Research Program (ORP) pre-announcement outlines anticipated funding opportunities supporting innovative, high-impact research to advance treatment and rehabilitation for orthopaedic injuries sustained during combat and service-related activities. This pre-announcement is intended to help teams plan now; it is not a promise of funding. Full Funding Opportunity Announcements (FOAs) with submission deadlines will be posted on Grants.gov and eBRAP when released.

How much funding would I receive?

Specific award budgets and totals are not yet provided in the pre-announcement. A sampling of anticipated mechanisms includes:

• Applied Research Award – up to $950,000 total costs over up to 3 years.

• Clinical Research Award (Level 1) – up to $2,000,000 total costs (4-year max).

• Clinical Research Award (Level 2) – up to $3,200,000 total costs (4-year max).
  (Total awards by mechanism and number of awards are not specified at this stage.)

What could I use the funding for?

Projects must address one or more of the FY26 ORP focus areas, including:

• Battlefield fracture-related infection (prevention, early detection, eradication strategies).

• Composite tissue regeneration following high-energy extremity trauma.

• Ligamentous trauma treatments for musculoskeletal soft-tissue instability.

• Limb stabilization and wound protectants enabling prolonged care.

• Osseointegration outcomes for prosthetic limb interfaces.

• Return-to-duty strategies to optimize reintegration and reduce reinjury.

• Military women’s health impacts of orthopaedic care.
  Funding applies to research that improves patient function, restores mobility, and maximizes return to duty in military and service-related contexts.

Are there any additional benefits I would receive?

The pre-announcement does not list additional benefits (e.g., mentoring, training, networking) beyond funding support.

What is the timeline to apply and when would I receive funding?

• Pre-announcement release: February 24, 2026.

• FOAs release: Posted later on Grants.gov and eBRAP (dates not yet specified).

• Pre-application and application deadlines: To be included in the full FOAs.

• Funding start dates: Determined after FOA release and award negotiations (not specified).
  (All deadlines and schedules will be in the final FOAs — not provided in this pre-announcement.)

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility for each award mechanism will be defined in the full FOAs. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms, particularly clinical research awards.

• Preproposal required: Some mechanisms require a preproposal through eBRAP, and full application is by invitation only.
  (Complete eligibility details — including institution types, citizenship, and cost share — will be in the FOAs and are not specified here.)

What companies and projects are likely to win?

Specific companies or project profiles most likely to win are not described in the pre-announcement. Competitive applications will align with the ORP focus areas and demonstrate potential to advance orthopaedic care in military and clinical contexts.

Are there any restrictions I should know about?

• The ORP will not consider applications proposing strategies infeasible in battlefield environments for fracture-related infection or tissue regeneration alone.

• The program will not consider biomarker-only research.

• Preproposal submission is required for certain mechanisms; full applications may be by invitation only.

• All submissions must comply with final FOA instructions posted on Grants.gov.

How long will it take me to prepare an application?

With deadlines and FOA details not yet posted, exact preparation time cannot be stated. Given CDMRP’s typical structure, planning should begin now to develop compelling science narratives, compliance documents, and required eBRAP preproposals.

How can BW&CO help?

BW&CO can help you:

• Monitor FOA release dates and mechanism details.

• Translate the final FOA into a targeted application roadmap.

• Develop high-impact narrative, budget, and compliance materials.

• Guide submission strategy on eBRAP and Grants.gov.

• Support preproposal and full application review to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

DIU: AI Assisted Triage & Treatment Challenge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The AI Assisted Triage & Treatment Challenge is a Defense Innovation Unit (DIU) prize challenge seeking portable, network-capable hemodynamic monitoring systems for forward combat medical environments. The goal is to enable real-time triage and predictive warning of dangerous physiological conditions in austere and Denied, Disrupted, Intermittent, and Limited (DDIL) settings.

Up to eight (8) finalists will share a $999,000 total prize pool and demonstrate at Sword 2026. Top performers may be invited to pursue a Prototype Other Transaction (OT) under 10 U.S.C. § 4022 without further competition.

Responses Due By: 2026-03-02 23:59:59 US/Eastern Time.

How much funding would I receive?

• $999,000 total prize pool, split among up to eight (8) finalist companies.

• Exact distribution per company is not specified.

• DIU has approved a budget and execution plan to negotiate Prototype Other Transaction (OT) projects pursuant to 10 U.S.C. § 4022 following Sword 26.

• The amount of any future OT award is not specified.

What could I use the funding for?

Prize funds are awarded through the Challenge.

If selected for a Prototype OT under 10 U.S.C. § 4022, funding would support development and prototyping of:

• Portable, network-capable hemodynamic monitoring devices

• Hardware, software, and networking components

• Demonstration and battlefield testing (up to 30 systems expected for Phase 3 testing)

Specific allowable cost categories are not detailed in the announcement.

Are there any additional benefits I would receive?

Selected teams may receive:

• Invitation to submit a Prototype OT proposal without further competition

• Participation in Sword 2026 (May 8–12, 2026)

• Engagement with DoW stakeholders and mission partners

• Potential participation in future exercises

• Consideration for scaling solutions into operational capabilities

DIU may assist in accelerating timelines for research approvals, subject to applicable processes and approvals.

What is the timeline to apply and when would I receive funding?

Responses Due By: 2026-03-02 23:59:59 US/Eastern Time.

All dates are tentative and subject to change.

Prize Challenge Phases 1–3

• Feb 17, 2026: Open Call Release

• Feb 26, 2026: AMA Session (11:00 AM ET)

• Mar 2, 2026: Open Call Submission Window Closes

• Week of Mar 9, 2026: Semi-finalists Notified

• Apr 7–8, 2026: Virtual Pitches & Interviews

• Apr 10, 2026: Finalists Notified

• May 8–12, 2026: Sword 2026 Demonstration Event

• Week of Jun 8, 2026: Winners Announced

Prototype OT Phase

• June 2026: Top performers from Sword 2026 may be invited to submit a proposal for a Prototype OT pursuant to 10 U.S.C. § 4022, without further competition.

Prize payment timing is not specified.

Where does this funding come from?

This Challenge is issued by the Defense Innovation Unit (DIU) in partnership with Project Manager Soldier Medical Devices and other Department of War (DoW) stakeholders.

Who is eligible to apply?

Eligibility includes:

• Any U.S. or International Participants (subject to security screening before acceptance to finals)

• Ability to demonstrate capabilities at a Department-determined test site in Europe by May 2026

• Small businesses and non-traditional defense vendors are encouraged to apply

If advancing to Phase 4 (Prototype OT), teams must either:

• Include at least one non-traditional defense contractor or non-profit research institution with significant participation, or

• Ensure at least one-third of total OT costs are paid by parties other than the government

Companies must:

• Register in SAM and obtain a CAGE code (if selected for a Prototype agreement)

Non-Traditional Defense Contractor definition is provided in accordance with 10 U.S.C 2302(9).

What companies and projects are likely to win?

The DoW seeks:

• Portable, ruggedized, lightweight hemodynamic monitoring devices

• Minimum 72-hour operation without recharge

• Wireless data transmission

• Predictive warning indicators for dangerous hemodynamic status

• Usability by medical and non-medically trained personnel

• Integration with DoW and allied systems (e.g., electronic health record, BATDOK, ATAK)

• Cloud and on-premise functionality

• Internal data logging for DDIL environments

Additional favorable attributes:

• Extensibility to TCCC, CASEVAC, MEDEVAC, resupply

• Rapid fielding capability and exportability to allies

• Existing ATO or system-of-record certification

• FedRAMP Moderate and DISA IL-5 (PA), with final product compliant with FedRAMP High

• U.S. National Security Facility Clearance

• Manufacturing capacity for up to 15,000 units in first production year

White papers are judged on:

1. Introduction

2. System Effectiveness

3. Technical Feasibility

4. System Scalability/Economics

5. Commercial Viability

6. Submission Quality

Are there any restrictions I should know about?

• White paper limited to five (5) pages, 11-point Calibri, single-spaced

• Must use provided template

• Submit as PDF

• Footnotes not permitted

• References must be within page limit

• Must acknowledge familiarity with DoW Ethical Principles for AI and DIU Responsible AI Guidelines

• Must comply with 32 CFR 219 and DoDI 3216.02 if human subjects research is required

• Medical devices must seek FDA 510(k) clearance (minimally in trauma patients) and receive clearance before procurement and fielding

• Vendors with cloud solutions must meet FedRAMP and DISA IL requirements as stated

• DIU reserves the right to cancel, suspend, or modify the Challenge

How long will it take me to prepare an application?

Preparation time will depend on:

• Maturity of your technical solution

• Readiness to address regulatory (FDA), security (FedRAMP, DISA IL-5), and manufacturing scale requirements

• Ability to align with Responsible AI Guidelines

How can BW&CO help?

BW&CO can support you by:

• Assessing eligibility and OT strategy

• Structuring your white paper against the six evaluation criteria

• Positioning your solution for both prize selection and follow-on Prototype OT

• Clarifying Responsible AI, regulatory, and security alignment narratives

• Preparing you for the April 7–8, 2026 pitch event

Our goal is to help you compete not just for the prize pool, but for the potential 10 U.S.C. § 4022 Prototype OT without further competition.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements for submitting application ($9,000) available.

Additional Resources

Review the solicitation here.